Upon completion, participants will have a high level knowledge of the challenges in delivering nucleic acid therapies in vivo and the benefits of nonviral delivery vehicles.
Upon completion, participants will be aware of the challenges associated with designing nonviral gene delivery vehicles.
Upon completion, participants will be aware of how machine learning can be employed to design nonviral gene delivery vehicles.
